SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sigmund who wrote (1242)1/22/1998 9:17:00 AM
From: Cisco  Read Replies (1) of 1894
 
®Are you or Cisco in a position to make a sales and operating profit forecast for the remainder of ACMI the part not contributed to NewCo?¯

Yes and No!

I had orginally forecasted sells at $35 million and Vector Securities has projected $34.4 million for 1998. These are probably still good numbers since AccuMed retain the AcCell and TracCell 2000 rights. If anything one would think that the relationship with Sakura distribution and open doors might increase this some.

R&D and administration expenses for AccuMed should be going down $3-4 million according to the conference call. I assuming that ACMI will be picking part of it back up as an expense of NewCo. The net effect should be higher ESP for 1998 than what I orginally projected.

I am still expecting to see a relatively poor performance for the fourth quarter 1997.

Cisco
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News